Citizens JMP raised the firm’s price target on Protagonist Therapeutics (PTGX) to $102 from $69 and keeps an Outperform rating on the shares. Protagonist Therapeutics has proven it can discover and develop differentiated pipeline candidates and the next wave of candidates are entering the clinic now, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $91 from $74 at Clear Street
- Protagonist Therapeutics Advances Pipeline Amid Financial Loss
- Promising Developments and Strategic Progress at Protagonist Therapeutics Drive Buy Rating
- Protagonist Therapeutics reports Q3 EPS (62c), consensus (64c)
- PTGX Earnings this Week: How Will it Perform?